HERON THERAPEUTICS INC (NASDAQ:HRTX) reported its fourth quarter and full-year 2025 financial results, delivering a top-line revenue beat while earnings per share came in slightly worse than analyst expectations. The commercial-stage biotech's stock is trading higher in pre-market activity, suggesting investors are focusing on strong revenue growth from its newer Acute Care products and an improved financial outlook for 2026.
Earnings and Revenue Versus Estimates
For the fourth quarter of 2025, Heron reported net revenue of $40.6 million, which edged past the consensus analyst estimate of $40.3 million. This represents a marginal decline of 0.5% compared to the $40.8 million reported in Q4 2024.
On the bottom line, the company reported a net loss of $2.95 million, or a loss of $0.02 per share. This was slightly wider than the estimated loss of $0.0204 per share anticipated by analysts. For the full year 2025, total net revenue reached $154.9 million, a 7.4% increase over 2024.
Market Reaction and Price Action
The immediate market reaction appears positive. Following the earnings release, HRTX shares are trading approximately 9.25% higher in pre-market activity. This upward move contrasts with the stock's recent performance, which has seen declines over the past month. The positive reaction suggests the market is rewarding the revenue beat and, more significantly, the company's forward guidance which points to improving profitability.
- Pre-Market Performance: +9.25%
- Last Month Performance: -22.86%
2026 Guidance and Analyst Comparison
A key driver of the positive sentiment is the company's financial guidance for the full year 2026. Heron provided its first outlook for Adjusted EBITDA, a closely watched measure of profitability.
- Net Revenue Guidance: $173 to $183 million.
- Adjusted EBITDA Guidance: $10 to $20 million.
This guidance signals a significant step toward operational profitability and provides a concrete benchmark for investors. While specific analyst estimates for 2026 revenue and EBITDA were not provided in the context, the mere issuance of this guidance, particularly the positive EBITDA range, is being interpreted as a strong positive signal about the company's trajectory and cost management.
Summary of Key Press Release Highlights
Beyond the financial figures, Heron's earnings report emphasized the accelerating commercial performance of its Acute Care franchise, which is now the central growth engine.
- Acute Care Franchise Growth: The franchise, comprising ZYNRELEF for postoperative pain and APONVIE for postoperative nausea and vomiting (PONV), grew 65.1% year-over-year for full-year 2025 to $49.6 million. In Q4, growth was 57.3%.
- Product-Specific Milestones: Both ZYNRELEF and APONVIE received permanent, product-specific J-Codes from CMS in 2025, which simplifies reimbursement and is expected to accelerate adoption in hospitals and surgical centers.
- Oncology Base: The established Oncology franchise (CINVANTI and SUSTOL) generated $105.3 million in 2025 revenue, providing a stable financial base despite a year-over-year decline.
- Balance Sheet: The company reported cash, cash equivalents, and short-term investments of $46.6 million as of December 31, 2025.
For a detailed look at Heron's historical earnings, future estimates, and analyst projections, you can review the data here.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, a recommendation, or an offer to buy or sell any security. Investing carries risks, including the potential loss of principal.